Factor V Leiden Thrombophilia malady

Categories: Rare diseases, Genetic diseases, Blood diseases

Aliases & Classifications for Factor V Leiden Thrombophilia

Aliases & Descriptions for Factor V Leiden Thrombophilia:

Name: Factor V Leiden Thrombophilia 71 23 50 24 25
Hereditary Resistance to Activated Protein C 23 50 24 25
Factor V Leiden Mutation 23 24 69
Apc Resistance, Leiden Type 50 25
Thrombophilia Due to Activated Protein C Resistance 69
Thrombosis Risk Factor 24
Thrombophilia V 24
Factor V R506q 24



Penetrance Factor v leiden heterozygotes identified from general population screening had a low absolute incidence of vte of approximately two vte events per 1000 persons per year in several studies [juul et al 2004, heit et al 2005]. the cumulative incidence of vte was 6.5% at age 65 years. homozygotes had an absolute incidence of 15 vte events/1000 persons/year [juul et al 2004]...


Summaries for Factor V Leiden Thrombophilia

NIH Rare Diseases : 50 factor v leiden thrombophilia is a genetic disorder that makes it more likely for you to develop a blood clot sometime during your life. still, it is estimated that 95% of people with factor v leiden never develop a clot. when a clot does form, the clot most often occurs in your leg (deep venous thrombosis or dvt) or lungs (pulmonary embolism or pe). factor v leiden is the name of a specific gene mutation in the f5 gene. this gene plays a role in how your body forms blood clots after an injury. people can inherit one or two copies of the factor v leiden gene mutation. last updated: 1/24/2017

MalaCards based summary : Factor V Leiden Thrombophilia, also known as hereditary resistance to activated protein c, is related to thrombophilia due to activated protein c resistance and thrombosis. An important gene associated with Factor V Leiden Thrombophilia is F5 (Coagulation Factor V). The drugs Heparin and Dalteparin have been mentioned in the context of this disorder. Affiliated tissues include lung.

Genetics Home Reference : 25 Factor V Leiden thrombophilia is an inherited disorder of blood clotting. Factor V Leiden is the name of a specific gene mutation that results in thrombophilia, which is an increased tendency to form abnormal blood clots that can block blood vessels.

GeneReviews: NBK1368

Related Diseases for Factor V Leiden Thrombophilia

Diseases related to Factor V Leiden Thrombophilia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 22)
id Related Disease Score Top Affiliating Genes
1 thrombophilia due to activated protein c resistance 11.5
2 thrombosis 10.7
3 cerebritis 10.4
4 budd-chiari syndrome 10.4
5 thrombophilia 10.2
6 retinitis 10.2
7 myocardial infarction 10.2
8 antiphospholipid syndrome 10.2
9 portal vein thrombosis 10.1
10 protein s deficiency 10.1
11 pulmonary embolism 10.1
12 inflammatory bowel disease 10.1
13 hepatitis 10.1
14 retinal vein occlusion 10.1
15 purpura 10.0
16 polycythemia 10.0
17 breast cancer 10.0
18 legg-calve-perthes disease 9.9
19 kienbock's disease 9.9
20 coronary artery disease 9.8
21 hemophilia 9.8
22 hemophilia a 9.8

Graphical network of the top 20 diseases related to Factor V Leiden Thrombophilia:

Diseases related to Factor V Leiden Thrombophilia

Symptoms & Phenotypes for Factor V Leiden Thrombophilia

Drugs & Therapeutics for Factor V Leiden Thrombophilia

Drugs for Factor V Leiden Thrombophilia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 772 46507594
Dalteparin Approved Phase 4,Phase 3 9041-08-1
3 calcium heparin Phase 4,Phase 3
4 Heparin, Low-Molecular-Weight Phase 4,Phase 3
5 Fibrinolytic Agents Phase 4,Phase 3
6 Anticoagulants Phase 4,Phase 3
7 Thrombin Phase 4
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
Rivaroxaban Approved Phase 3 366789-02-8
10 Analgesics Phase 3
11 Acetylsalicylic acid lysinate Phase 3
12 Cyclooxygenase Inhibitors Phase 3
13 Analgesics, Non-Narcotic Phase 3
14 Peripheral Nervous System Agents Phase 3
15 Pharmaceutical Solutions Phase 3
16 Platelet Aggregation Inhibitors Phase 3
17 Anti-Inflammatory Agents Phase 3
18 Anti-Inflammatory Agents, Non-Steroidal Phase 3
19 Antipyretics Phase 3
20 Antirheumatic Agents Phase 3
protease inhibitors Phase 3
22 Serine Proteinase Inhibitors Phase 3
23 HIV Protease Inhibitors Phase 3
24 Factor Xa Inhibitors Phase 3
25 Antithrombin III Phase 3
26 Antithrombins Phase 3
27 serine Nutraceutical Phase 3
28 Nadroparin Approved 9041-08-1
29 Estrogens
30 Coagulants
31 protein S
32 Factor VIII
33 Immunoglobulins
34 Protein C
35 Antibodies
36 Antibodies, Antiphospholipid
37 Kava Nutraceutical 9000-38-8

Interventional clinical trials:

(show all 16)
id Name Status NCT ID Phase
1 Low Molecular Weight Heparin in Prevention of Recurrent Arteriovenous Graft Thrombosis in Chronic Hemodialysis Patients. Unknown status NCT01970280 Phase 4
2 LMWH to Prevent Preeclampsia and Fetal Growth Restriction Terminated NCT00260520 Phase 4
3 Prevention of Maternal and Perinatal Complications by Enoxaparin in Women With Previous Severe Preeclampsia Completed NCT00986765 Phase 3
4 A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients Recruiting NCT02111564 Phase 3
5 Prevention of Unexplained Recurrent Abortion by Enoxaparine Terminated NCT00740545 Phase 3
6 Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome Completed NCT02833194
7 Determination of Performance Characteristics of the MassPLEX Factor II/V Leiden Test Completed NCT01835483
8 Factor V Leiden Mutation and Implantation Failure Completed NCT00194350
9 Effect of DT56a (Femarelle) on the Coagulation System in the Treatment of Postmenopausal Women Completed NCT00883272
10 Study of Abnormal Blood Clotting in Children With Stroke Completed NCT00001927
11 Thrombophilic Risk Factors in Pediatric Patients Diagnosed at the Ha'Emek Medical Center Completed NCT00736008
12 Study on Antithrombotic Prevention in Thrombophilia and Pregnancy Loss Recruiting NCT02385461
13 Substudy - Evaluation of Patients With Iliac Vein Thrombosis Recruiting NCT03148548
14 Thrombophilic Risk Factors in Preterm and Infants Treated at Ha'Emek Medical Center Between the Years 1990 to 2010 Recruiting NCT01443273
15 Leiden Trial In Prevention of Post-Operative ThromboEmbolic Events Not yet recruiting NCT02987946
16 Comparative Prevalence of Psychiatric Manifestations in Purely Obstetrical Antiphospholipid Syndrome Terminated NCT01649479

Search NIH Clinical Center for Factor V Leiden Thrombophilia

Genetic Tests for Factor V Leiden Thrombophilia

Genetic tests related to Factor V Leiden Thrombophilia:

id Genetic test Affiliating Genes
1 Factor V Leiden Thrombophilia 24 F5

Anatomical Context for Factor V Leiden Thrombophilia

MalaCards organs/tissues related to Factor V Leiden Thrombophilia:


Publications for Factor V Leiden Thrombophilia

Articles related to Factor V Leiden Thrombophilia:

id Title Authors Year
Bilateral Legg-Calve-Perthes Disease and Kienbock's Disease in a Child With Factor V Leiden Thrombophilia: A Case Report. ( 27698645 )
Factor V leiden thrombophilia in a female collegiate soccer athlete: a case report. ( 23675803 )
Factor V Leiden thrombophilia. ( 21116184 )
Factor V Leiden thrombophilia: presentation of three patients and a literature review. ( 19610561 )
Factor V Leiden Thrombophilia ( 20301542 )

Variations for Factor V Leiden Thrombophilia

Expression for Factor V Leiden Thrombophilia

Search GEO for disease gene expression data for Factor V Leiden Thrombophilia.

Pathways for Factor V Leiden Thrombophilia

GO Terms for Factor V Leiden Thrombophilia

Sources for Factor V Leiden Thrombophilia

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
65 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....